Shana Thomas

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

X. Cynthia, Feng Gao, Jingqin Luo et al. · Clinical Cancer Research · 2017 · 376 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer

X. Cynthia, Ron Bose, Feng Gao et al. · Clinical Cancer Research · 2017 · 191 citations · Full text

Medicine, Oncology, Pharmacology +15

Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer

Jing Xi, Shana Thomas, Foluso O. Ademuyiwa et al. · Journal of the National Comprehensive Cancer Network · 2019 · 101 citations

Medicine, Oncology, Pharmacotherapy +16

A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer

X. Cynthia, Jingqin Luo, Michael Naughton et al. · Clinical Cancer Research · 2015 · 93 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

Nusayba A. Bagegni, Shana Thomas, Ning Liu et al. · Breast Cancer Research · 2017 · 71 citations · Full text

Medicine, Oncology, Pharmacology +17